Acadia Pharmaceuticals | ACAD - Assets


Acadia Pharmaceuticals reported $1.61B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
ALKERMES USD 4.26B 1.77B Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Cara Therapeutics USD 32.07M 6.95M Dec/2025
Corcept Therapeutics USD 814.88M 21.77M Mar/2026
Cytokinetics USD 1.27B 151.06M Mar/2026
Eisai JPY 1.45T 37.11B Mar/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Moderna USD 11.49B 850M Mar/2026
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Prothena USD 349.89M 23.09M Mar/2026
PTC Therapeutics USD 2.87B 29.66M Mar/2026
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026